AVO Stock Overview
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Advanced Oncotherapy plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.018 |
52 Week High | UK£0.18 |
52 Week Low | UK£0.018 |
Beta | 0.061 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -89.71% |
33 Year Change | -94.26% |
5 Year Change | -95.51% |
Change since IPO | -99.79% |
Recent News & Updates
Shareholder Returns
AVO | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 0% | -1.5% | 1.0% |
1Y | -89.7% | -1.1% | 6.3% |
Return vs Industry: AVO underperformed the UK Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: AVO underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
AVO volatility | |
---|---|
AVO Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 6.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.2% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AVO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AVO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 174 | Nicolas Serandour | www.avoplc.com |
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties.
Advanced Oncotherapy plc Fundamentals Summary
AVO fundamental statistics | |
---|---|
Market cap | UK£9.50m |
Earnings (TTM) | -UK£32.60m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs AVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AVO income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£32.60m |
Earnings | -UK£32.60m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.06 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 39.6% |
How did AVO perform over the long term?
See historical performance and comparison